PGT-A Testing and IVF: What the Research Actually Says and Whether You Need It

If you have been through an IVF consultation recently, there is a good chance the topic of PGT-A came up. Perhaps your clinic recommended it. Perhaps they presented it as something most patients in your situation choose to do. Or perhaps you came across it in your own research and found yourself in a maze of conflicting opinions, clinical papers, and very strong feelings on both sides of the debate.

You are not imagining the confusion. PGT-A is one of the most genuinely contested topics in reproductive medicine right now. Here is what you need to know.

What Is PGT-A?

PGT-A stands for Preimplantation Genetic Testing for Aneuploidies. In plain language, it is a genetic test carried out on embryos created through IVF before they are transferred to the uterus.

The testing involves taking a small biopsy,  usually a few cells,  from a five-day-old embryo (a blastocyst). Those cells are sent to a genetics laboratory, which analyses the chromosomal makeup of the embryo. The aim is to identify embryos that are euploid (the correct number of chromosomes) versus aneuploid (too many or too few chromosomes).

The idea is that by only transferring chromosomally normal embryos, you reduce the risk of implantation failure and miscarriage, and improve the chances of a healthy live birth.

Why Is It Controversial?

PGT-A sounds logical in theory. The complications arise in practice.

The mosaic embryo question. Not all embryos are uniformly chromosomally normal or abnormal. Some are 'mosaic';  they contain a mix of normal and abnormal cells. Earlier versions of PGT-A testing would have discarded these embryos. More recent research has shown that mosaic embryos can result in healthy pregnancies and live births. This has forced a significant rethink in how results are interpreted, and has raised important questions about how many viable embryos may have been unnecessarily discarded in the past.

The biopsy itself carries risk. Removing cells from a blastocyst is not a neutral act. Although the risk is small in experienced hands, there is evidence that embryo biopsy can reduce the implantation potential of some embryos. This has to be weighed against any potential benefit.

The testing is not perfect. PGT-A cannot detect every type of genetic abnormality, only chromosomal number errors (aneuploidies). It does not assess the embryo for single-gene disorders unless you specifically undergo PGT-M testing, which is a separate and more complex process.

Younger patients may not benefit. Several large randomised controlled trials have found that PGT-A does not improve cumulative live birth rates in younger women (generally under 35) with a good embryo cohort.

Who Is Most Likely to Benefit From PGT-A?

The picture is more consistently supportive for certain groups:

• Women over 37–38 using their own eggs, where the rate of chromosomal abnormality in embryos is higher, and testing can help prioritise the most viable embryo for transfer
• Women with recurrent implantation failure — multiple failed transfers of apparently good-quality embryos
• Women with recurrent miscarriage, particularly where the cause may be chromosomally abnormal embryos
• Couples where the male partner has severe sperm abnormalities

For these patients, the evidence is more compelling that PGT-A can improve the efficiency of treatment — reducing the number of failed transfers needed to achieve success.

What Does PGT-A Cost?

In the UK, PGT-A is a private add-on and is not covered by NHS funding. Costs typically include:

• Embryo biopsy per cycle: £1,000–£2,000
• Genetic analysis per embryo: £200–£400 per embryo tested
• Frozen embryo transfer cycle (required after testing): £1,500–£3,000

For a patient with four embryos to test, the total add-on cost can easily reach £3,000–£4,500 or more, on top of the base IVF cycle costs.

What the HFEA Says

The Human Fertilisation and Embryology Authority (HFEA) rates IVF add-ons using a traffic light system. As of 2024, PGT-A is rated amber, meaning there is some evidence of benefit for certain patient groups, but the evidence is not strong enough to recommend it universally. The HFEA advises patients to discuss their individual circumstances with their Doctor rather than assuming it is appropriate for everyone..

Questions to Ask Your Clinic

•  Based on my age and diagnosis, what evidence supports PGT-A being beneficial in my specific situation?
• What is your policy on mosaic embryos,  will they be automatically discarded, or will they be considered for transfer?
• What laboratory are you using for analysis, and what is their concordance rate?
• What happens if all my embryos come back as aneuploid? Will we revisit the results together?

The answers to these questions will tell you a great deal about the quality and transparency of the clinic you are working with.

The Bottom Line

PGT-A is a genuinely useful tool in the right hands, for the right patients. For women over 38 with multiple embryos, or for those who have experienced repeated failure or miscarriage, it can meaningfully improve the efficiency of their IVF journey. For younger women with no history of failure, the benefit is far less clear.

What matters most is that this decision is made collaboratively, between you and a clinician who knows your full history, understands the nuance in the evidence, and respects your right to make an informed choice. Testing for its own sake, without clear clinical reasoning, is not something anyone should feel pressured into.

You deserve clarity, not upselling.